FDA warns AlzClipp/UniUni that its AlzClipp nasal product is an unapproved new drug and misbranded with false FDA approval claims.
What happened
FDA reviewed the company's product labeling and website at alzclipp.com in July 2025 and found the AlzClipp nasal product offered for sale in the United States. The label and website claim the product boosts memory, prevents Alzheimer's disease, reverses dementia, and treats memory decline. FDA also found an FDA logo with 'FDA approved' and a certificate headline saying 'FDA Approves AlzClipp' even though there is no FDA-approved application for the product.
What FDA found
AlzClipp is a drug because its label and website claim it prevents or treats Alzheimer's disease, dementia, and memory decline.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)AlzClipp is an unapproved new drug because there is no FDA-approved application for it.
sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d); section 201(p), 21 U.S.C. 321(p)The website is false or misleading because it uses an FDA logo and says 'FDA approved' and 'FDA Approves AlzClipp' even though FDA has not approved the product.
section 502(a) of the FD&C Act, 21 U.S.C. 352(a); section 301(a), 21 U.S.C. 331(a)
What FDA wants
FDA tells the company to notify FDA in writing within 15 working days of receipt of the letter about specific steps taken to correct the violations and prevent recurrence. If the company believes the product is not in violation, it must include its reasoning and supporting information.
Who should pay attention
- companies selling nasal or cognitive-health products with disease claims
- online retailers and marketplaces listing unapproved drugs
- labeling and advertising reviewers who check FDA approval claims
This is a summary. Read the original letter on fda.gov.